Filing Details

Accession Number:
0000899243-20-018817
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-09 16:18:32
Reporting Period:
2020-07-08
Accepted Time:
2020-07-09 16:18:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1680581 Fulcrum Therapeutics Inc. FULC Pharmaceutical Preparations (2834) 474839948
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1778843 B. Owen Wallace C/O Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge MA 02139
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-07-08 2,951 $7.84 130,039 No 4 M Direct
Common Stock Disposition 2020-07-08 2,951 $20.00 127,088 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-07-08 2,951 $0.00 2,951 $7.84
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
81,942 2029-01-21 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.
  2. The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.